False
By Stephanie Vine
July 14, 2025
What comes next for cancer drug development? AbbVie’s Eleni Lagkadinou discusses precision, AI, and her hope for turning cancer into a more chronic, manageable condition.
11 min read
July 4, 2025
Following another appearance in our 2025 Power List, we discuss the journey of John Maher, co-founder and CSO, Leucid Bio, from Michel Sadelain’s New York lab to King’s College London.
5 min read
By Stephanie Vine
May 2, 2025
From a love of history books to a love of CRISPR, Monika Paule tells us the story of her career and the origins of Caszyme.
8 min read
By Stephanie Vine
April 25, 2025
Depending on the country, only about two in 10 eligible patients, on average, receive CAR T-cell therapy. We sat down with Kite’s Cindy Perettie to talk about access to CAR Ts.
9 min read
By Stephanie Vine
April 21, 2025
In Part 1 of our interview with Simon Tasker, he explained how he joined Colorcon as a bench chemist – and never left...
5 min read
By Stephanie Vine
April 17, 2025
After his postdoc, Simon Tasker joined Colorcon as a bench chemist – and never left. Today, he’s the company’s CEO. Here’s how his career unfolded as he grew within the company he now leads.
5 min read
April 16, 2025
Discussing the development of trends, treatments, and talent in gene therapy with NewBiologix CEO Igor Fisch.
4 min read
By Stephanie Vine
April 15, 2025
We interview Lore Gruenbaum about The Leukemia & Lymphoma Society, advances in blood cancers, and how the field has seen many therapeutic firsts for the industry.
6 min read
By Stephanie Vine
April 9, 2025
Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society; because there are some goals you can only accomplish in a not-for-profit environment.
7 min read
March 3, 2025
From the GSK boardroom to the White House, and now the board of Abzena, the career path of Moncef Slaoui has resulted in billions of doses of lifesaving vaccines. Here he shares his story.
5 min read
False